Next 10 |
home / stock / akblf / akblf news
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the Board of Directors has adopted a new corporate strategy (Allergy + ) and 2028 financial ambitions. Allergy + aims to further strengthen ALK’s leadership in allergy immunotherapy, establishing a leading position...
2024-05-05 04:03:38 ET ALK-Abelló A/S (AKBLF) Q1 2024 Results Conference Call May 03, 2024 06:30 AM ET Company Participants Per Plotnikof - Head of Investor Relations Peter Halling - Chief Executive Officer Claus Steensen Solje - Chief Financial Officer ...
Company release No. 11/2024 ALK delivers 10 % organic revenue growth with operating profit up 41 % in Q1 and upgrades outlook The growth in ALK's overall sales was primarily driven by the European tablet sales, which were boosted by the inflow of new patients and improved ...
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the B...
08 February 2024 ALK’s ( ALKB:DC / OMX: ALK B / AKBLF ) Board of Directors has approved the company’s 2023 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook. ALK expects to continue its growth trajectory and earning...
The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension. ALK ( ALKB:DC / OMX: ALK B / AKBLF ) announced today that it has completed the first part of its phase 1 clinical trial...
ALK to Become Sole Manufacturer and Distributor of Skin Antigen Test for Penicillin Allergy Canada NewsWire – PRE-PEN ® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergy i,ii ...
ALK delivers 8 % revenue growth with operating profit up 128 % in Q3 (unaudited) ALK saw growth in all sales regions in Q3, led by sales of tablets and SCIT. As expected, European tablet sales picked up and grew by 14%, mainly driven by new patient initiations. Operating p...
ALK delivers 11 % revenue growth with operating profit up 120 % in Q2 (unaudited) ALK’s revenue grew by 11% in Q2 2023, driven by 17% growth in tablet sales and double-digit growth in combined SCIT/SLIT-drops sales. Operating profit (EBIT) increased by 120% in loc...
Primary and all key secondary confirmatory endpoints w ere met, with a n improvement in the total combined allergic rhinitis score (TCRS) of 22 % compared to placebo (primary endpoint) . Results were highly statistically sign...
News, Short Squeeze, Breakout and More Instantly...
Alk-Abello A/S Company Name:
AKBLF Stock Symbol:
OTCMKTS Market:
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the Board of Directors has adopted a new corporate strategy (Allergy + ) and 2028 financial ambitions. Allergy + aims to further strengthen ALK’s leadership in allergy immunotherapy, establishing a leading position...
Company release No. 11/2024 ALK delivers 10 % organic revenue growth with operating profit up 41 % in Q1 and upgrades outlook The growth in ALK's overall sales was primarily driven by the European tablet sales, which were boosted by the inflow of new patients and improved ...
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the B...